No definition available.
Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
E4_HYPERURI
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
196 |
4. Check minimum number of eventsNone |
196 |
5. Include endpointsNone |
196 |
6. Filter based on genotype QC (FinnGen only) |
178 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E79
- Name in latin
- Hyperurichaemia sine symptomatibus arthritidis inflammatoriae sive morbi tophacei
Similar endpoints
↥List of similar endpoints to
Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
based on the number of shared cases.
Similar with more cases:
- Disorders of purine and pyrimidine metabolism
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1098 | 486 | 606 |
| Only index persons | 956 | 413 | 543 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 67.61 | 70.73 | 65.06 |
| Only index persons | 65.92 | 68.15 | 64.22 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 178 | 66 | 112 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | 66.00 | 64.74 | 66.75 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 183
- Matched controls
- 1830
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E79.0
ICD-10 Finland
Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
+∞
264.8
183
*
M04AA01
ATC
allopurinol; systemic
17.2
88.0
118
175
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
14.8
47.8
48
43
M10.9
ICD-10 Finland
Gout, unspecified
11.1
44.4
56
70
M10.0
ICD-10 Finland
Idiopathic gout
13.2
31.1
32
29
C03CA01
ATC
furosemide; systemic
3.9
18.4
100
435
H02AB06
ATC
prednisolone; systemic
3.9
17.0
125
652
M13.9
ICD-10 Finland
Arthritis, unspecified
6.1
17.0
33
64
205
Kela drug reimbursment
Chronic hypertension
3.7
16.8
82
328
212
Kela drug reimbursment
Gout
19.1
16.6
25
15
A46
ICD-10 Finland
Erysipelas
4.1
15.2
53
167
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.3
15.1
48
141
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.3
14.4
44
125
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
5.9
14.4
28
54
C07AB07
ATC
bisoprolol; oral
3.5
14.4
127
715
N17.9
ICD-10 Finland
Acute renal failure, unspecified
13.0
14.3
25
22
A10BH05
ATC
linagliptin; oral
6.1
14.0
26
48
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
6.0
13.7
26
49
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.3
12.9
69
284
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
12.8
121
690
I50.9
ICD-10 Finland
Heart failure, unspecified
3.6
12.8
53
186
E66.00
ICD-10 Finland
Metabolic syndrome
6.4
12.6
22
38
A10BA02
ATC
metformin; oral
3.1
12.6
77
343
103
Kela drug reimbursment
Diabetes, insulin-treated
3.1
12.3
75
332
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
5.6
12.3
25
50
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.3
12.3
27
58
I10
ICD-10 Finland
Essential (primary) hypertension
3.6
12.2
144
925
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.2
11.6
26
57
C10AA01
ATC
simvastatin; oral
2.9
11.6
100
534
C10AA05
ATC
atorvastatin; oral
2.9
11.4
102
554
E66.01
ICD-10 Finland
Obesity due to excess calories
4.8
11.3
28
67
C08CA01
ATC
amlodipine; oral
2.9
11.1
99
534
288
Kela drug reimbursment
Febuxostat
46.3
11.1
13
*
C03DA01
ATC
spironolactone; oral
3.7
10.5
39
126
T90
ICPC
Diabetes non-insulin dependent
2.9
10.4
65
288
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
3.3
10.3
47
173
A10BK01
ATC
dapagliflozin; oral
4.6
10.3
26
63
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.8
10.3
74
354
P01BA02
ATC
hydroxychloroquine; oral
4.2
10.2
30
82
349
Kela drug reimbursment
Febuxostat
42.6
10.1
12
*
M04AA03
ATC
febuxostat; oral
42.6
10.1
12
*
E86
ICD-10 Finland
Volume depletion
42.6
10.1
12
*
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
27.8
10.0
13
5
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.9
9.9
62
274
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
5.8
9.9
19
36
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.0
9.8
57
242
J01DB01
ATC
cefalexin; oral
4.5
9.7
165
1227
A07EC01
ATC
sulfasalazine; oral, rectal
4.4
9.7
26
66
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
3.9
9.7
31
90
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
16.2
9.7
15
10
N18.8
ICD-10 Finland
Other chronic renal failure
13.4
9.6
16
13
J01FF01
ATC
clindamycin; systemic
2.7
9.5
71
343
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.3
9.3
40
142
C09CA03
ATC
valsartan; oral
3.8
9.1
30
89
L28
ICPC
Limited function/disability (L)
2.9
8.9
53
226
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
3.5
8.9
35
117
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.5
8.8
33
107
AN1
HP
Coronary angiography
3.6
8.7
32
102
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.7
8.7
61
284
A10AC01
ATC
insulin (human); parenteral
4.2
8.7
25
67
H02AB07
ATC
prednisone; oral
3.2
8.4
38
138
E66.8
ICD-10 Finland
Other obesity
8.8
8.3
17
21
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
12.5
8.2
14
12
G47.3
ICD-10 Finland
Sleep apnoea
2.7
8.2
60
284
I50.0
ICD-10 Finland
Congestive heart failure
3.7
8.2
28
85
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
2.6
8.1
62
300
A10AB05
ATC
insulin aspart; parenteral
3.9
8.0
25
71
A11CC03
ATC
alfacalcidol; systemic
13.9
8.0
13
10
E66.9
ICD-10 Finland
Obesity, unspecified
9.1
8.0
16
19
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.7
7.9
27
82
M01AB01
ATC
indometacin; systemic, rectal
3.5
7.6
28
89
L04AX03
ATC
methotrexate; systemic
3.4
7.6
30
100
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.9
7.5
41
166
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
11.6
7.4
13
12
C08CA13
ATC
lercanidipine; oral
2.9
7.4
41
167
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.0
7.2
36
138
N17.8
ICD-10 Finland
Other acute renal failure
21.0
7.2
10
5
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
21.0
7.2
10
5
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
2.7
7.2
47
209
N19
ICD-10 Finland
Unspecified kidney failure
6.8
7.1
17
27
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
3.9
7.1
22
62
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.3
7.0
28
94
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.3
6.9
28
95
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.3
6.9
77
438
E87.6
ICD-10 Finland
Hypokalaemia
17.5
6.8
10
6
R50.9
ICD-10 Finland
Fever, unspecified
2.8
6.8
40
168
A10AE05
ATC
insulin detemir; parenteral
4.3
6.8
18
45
A10AE04
ATC
insulin glargine; parenteral
3.3
6.7
27
91
C02AC05
ATC
moxonidine; oral
5.8
6.7
18
34
JFA15
NOMESCO Finland
Endoscopic polypectomy in colon
3.7
6.7
22
65
A02BC02
ATC
pantoprazole; systemic
2.5
6.6
140
1034
M10
ICD-10 Finland
Gout
4.4
6.5
17
42
R06.0
ICD-10 Finland
Dyspnoea
2.3
6.5
66
359
C01DA14
ATC
isosorbide mononitrate; oral
2.7
6.4
39
167
C09AA02
ATC
enalapril; systemic
2.5
6.4
51
249
TPH07
NOMESCO Finland
Cathetrisation of artery
3.1
6.3
29
106
J01MA14
ATC
moxifloxacin; systemic
3.2
6.3
26
89
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.5
6.3
46
215
E87.5
ICD-10 Finland
Hyperkalaemia
27.7
6.3
8
*
I25.1
ICD-10 Finland
Atherosclerotic heart disease
2.4
6.1
52
260
ZXD05
NOMESCO Finland
Urgent procedure
2.3
6.1
61
328
C09CA01
ATC
losartan; oral
2.3
6.1
61
328
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.6
6.0
40
178
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.3
6.0
59
314
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
137
423
9.91
48.89
6.7
2.8
406.91
352.68
umol/l
4.64
127
364
46
100
5.81
21.24
8.4
3.3
117.24
80.56
ng/l
1.45
41
85
75
251
4.37
20.43
4.8
2.2
2.24
2.24
g/l
0.02
69
236
78
274
4.22
19.80
4.7
2.2
10.54
13.21
umol/l
2.83
71
254
133
726
4.04
16.83
16.4
6.6
1.20
1.21
mmol/l
1.20
125
662
54
163
4.28
16.51
9.6
4.3
1.90
1.58
mmol/l
0.25
43
141
139
793
4.13
16.21
17.8
7.1
1.19
1.21
mmol/l
1.23
120
678
41
112
4.43
14.14
2.5
1.6
—
—
—
0
0
121
667
3.40
14.08
3.1
2.2
74.50
76.44
nmol/l
0.30
112
585
58
222
3.36
12.16
2.0
1.8
—
—
—
0
0
100
531
2.95
11.72
6.7
3.8
22.31
4.63
mg/mmol
2.39
82
328
26
57
5.15
11.60
6.8
2.4
23.96
25.24
mmol/l
0.56
26
57
100
535
2.92
11.50
5.6
3.1
6.60
8.02
mmol/l
3.59
92
439
138
881
3.30
11.46
17.5
11.1
4.68
4.09
e9/l
2.38
126
781
60
245
3.16
11.19
1.4
1.3
25.38
9.38
u/ml
0.76
22
97
59
241
3.14
10.98
1.9
1.7
—
—
—
0
0
51
195
3.24
10.56
11.3
8.8
1.02
1.03
mmol/l
0.00
37
164
67
301
2.93
10.47
2.1
1.8
—
—
—
0
0
36
116
3.62
9.70
14.2
7.4
90.35
93.62
%
0.60
36
116
88
474
2.65
9.51
2.5
2.1
140.33
169.92
u/l
0.63
83
445
44
164
3.22
9.42
12.4
10.0
116.75
122.75
g/l
0.98
44
158
96
542
2.62
9.38
6.2
3.2
3240.45
1149.86
ng/l
2.07
89
456
21
46
5.03
9.33
1.8
1.3
—
—
—
0
0
127
825
2.76
9.26
6.5
3.8
0.00
0.01
estimate
0.50
36
180
126
818
2.73
9.15
6.4
3.8
0.03
0.00
estimate
0.49
35
178
20
43
5.10
9.06
1.5
1.3
—
—
—
0
0
78
407
2.60
8.86
3.0
2.0
3.87
3.14
mg/l
1.42
70
355
36
123
3.40
8.84
4.7
2.4
38.04
61.66
ml/min/173m2
4.98
24
44
127
837
2.69
8.79
6.5
3.9
8.57
1.76
estimate
0.35
35
170
58
266
2.73
8.48
1.6
1.3
70.45
32.76
iu/ml
0.70
23
83
112
703
2.53
8.46
2.5
2.0
80.66
96.40
pmol/l
3.02
68
373
21
50
4.61
8.45
2.4
1.7
—
—
—
0
0
28
84
3.75
8.33
1.9
1.3
—
—
—
0
0
30
99
3.43
7.74
5.8
3.6
2.59
1.73
mmol/l
0.43
19
79
19
46
4.49
7.48
1.9
1.7
—
—
—
0
0
85
492
2.36
7.41
2.1
1.7
20.95
20.82
nmol/l
0.02
76
405
80
452
2.37
7.36
5.7
3.1
0.64
0.34
e6/l
0.92
69
334
36
137
3.03
7.35
3.0
2.6
3.08
7.24
ug/l
1.53
31
125
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
34
6.11
7.30
3.9
2.1
0.22
0.36
iu/ml
1.44
12
21
102
648
2.30
7.04
5.5
2.7
202.47
149.13
ug/l
0.92
95
601
19
49
4.21
6.90
2.2
1.7
—
—
—
0
0
20
55
3.96
6.68
1.6
1.2
—
—
—
0
0
12
12
10.60
6.64
2.7
1.1
1258.00
784.50
mg
0.30
12
12
148
1123
2.66
6.55
8.4
4.5
21.39
12.16
mm/h
7.17
143
1038
83
495
2.24
6.55
6.7
3.9
0.00
0.00
estimate
-0.00
31
159
16
28
6.16
6.31
6.1
2.4
16.65
16.30
%
0.13
16
28
54
272
2.40
6.29
2.1
1.6
1398.60
1229.50
nmol/l
0.59
45
208
51
252
2.42
6.19
3.5
2.0
29.18
29.29
s
0.05
51
243
14
23
6.50
5.82
1.5
1.5
—
—
—
0
0
98
650
2.09
5.66
6.8
3.8
39.98
83.55
ng/l
0.43
83
497
16
43
3.98
5.50
2.0
1.5
—
—
—
0
0
14
25
5.97
5.50
5.5
1.8
11.64
5.96
pmol/l
1.48
14
25
15
30
5.35
5.39
1.9
1.9
—
—
—
0
0
18
54
3.59
5.32
1.5
1.3
0.06
0.00
g/l
0.48
18
48
53
288
2.18
5.05
4.5
2.8
0.85
0.96
e6/l
0.18
37
162
96
650
2.00
5.05
6.6
3.8
3.55
0.02
estimate
0.50
29
149
13
24
5.74
5.02
3.5
2.2
32.54
32.79
pg
0.09
13
24
62
362
2.08
4.89
7.1
4.2
1.02
1.02
kg/l
0.23
52
247
18
59
3.27
4.66
1.6
1.6
2.27
8.93
iu/ml
—
6
18
15
45
3.54
4.43
2.1
1.5
—
—
—
0
0
14
35
4.24
4.20
2.0
1.5
—
—
—
0
0
98
701
1.86
4.09
4.4
3.0
—
—
estimate
—
0
0
26
113
2.52
4.08
4.0
3.7
445.38
186.04
ng/l
1.11
26
102
11
23
5.02
3.94
2.8
1.6
1.71
1.53
mmol/l
0.39
11
23
15
49
3.25
3.90
3.3
2.6
1.27
1.91
ratio
—
8
26
14
38
3.90
3.89
1.6
1.4
310.00
259.07
ug/g
—
8
19
16
55
3.09
3.84
1.4
1.2
0.00
0.00
g/l
-0.00
16
47
14
39
3.80
3.79
1.8
1.4
—
—
—
0
0
45
255
2.01
3.75
4.9
3.0
3.42
1.57
e6/l
0.88
27
129
8
14
5.92
3.38
2.0
1.6
—
—
—
0
0
33
173
2.11
3.37
5.1
3.6
—
—
—
0
0
9
20
4.67
3.15
1.3
1.5
—
—
—
0
0
16
62
2.73
3.14
2.4
3.1
—
—
—
0
0
8
17
4.87
2.95
1.4
1.2
—
—
—
0
0
49
310
1.79
2.88
1.4
1.2
0.69
2.05
u/ml
0.99
19
81
57
378
1.74
2.85
3.7
2.6
—
—
—
0
0
8
18
4.60
2.83
1.8
2.1
—
—
—
0
0
51
329
1.76
2.80
1.9
1.8
475.76
422.93
pmol/l
0.51
45
273
119
962
1.68
2.78
4.6
3.4
61.95
48.20
u/l
1.27
112
904
5
6
8.52
2.76
1.4
1.5
—
—
—
0
0
7
14
5.15
2.75
1.3
1.5
—
—
—
0
0
11
37
3.10
2.53
1.6
1.2
—
—
—
0
0
7
16
4.50
2.50
4.0
2.9
—
—
—
0
0
33
193
1.87
2.48
22.3
7.0
—
—
—
0
0
11
38
3.01
2.46
1.6
1.2
—
—
—
0
0
131
1104
1.66
2.43
5.3
4.1
15.32
15.03
pmol/l
0.76
119
995
5
8
6.39
2.38
1.0
1.0
—
—
—
0
0
7
17
4.24
2.38
2.7
2.1
—
—
—
0
0
7
17
4.24
2.38
1.9
2.2
—
—
—
0
0
7
17
4.24
2.38
2.7
2.1
—
—
—
0
0
7
17
4.24
2.38
2.7
2.1
—
—
—
0
0
10
34
3.05
2.32
1.9
1.4
—
—
—
0
0
165
1494
2.06
2.27
41.8
16.5
26.51
26.24
mg/l
0.05
160
1246
152
1342
1.78
2.26
6.6
5.1
1.98
1.93
mu/l
0.21
146
1206
11
41
2.79
2.25
1.4
1.6
—
—
—
0
0
7
19
3.79
2.17
1.0
1.0
—
—
—
0
0
6
14
4.39
2.17
8.5
3.8
1.00
0.93
%
—
6
14
13
56
2.42
2.10
1.5
1.3
—
—
—
0
0
5
10
5.10
2.08
1.0
1.0
145.80
356.90
u/l
—
5
10
6
15
4.10
2.05
1.3
1.2
—
—
—
0
0
9
32
2.90
2.03
1.3
1.2
—
—
—
0
0
97
783
1.51
2.00
2.9
2.7
—
—
—
0
0
63
464
1.55
2.00
5.2
3.2
0.44
0.19
estimate
0.29
32
139
5
11
4.64
1.95
1.2
1.0
—
—
—
0
0
5
11
4.64
1.95
1.2
1.0
—
—
—
0
0
6
17
3.61
1.85
1.5
1.2
—
—
—
0
0
19
102
1.96
1.84
2.1
1.7
—
—
—
0
0
5
12
4.25
1.83
1.4
1.2
—
—
—
0
0
5
12
4.25
1.83
1.6
1.1
—
—
—
0
0
5
12
4.25
1.83
1.4
1.1
—
—
—
0
0
5
15
3.40
1.53
3.4
2.7
—
—
—
0
0
7
29
2.47
1.40
1.4
1.3
—
—
—
0
0
7
29
2.47
1.40
1.4
1.3
—
—
—
0
0
5
18
2.83
1.29
7.6
2.2
4.72
3.96
nmol/l
—
5
18
155
1433
1.53
1.27
11.1
6.4
43.16
39.30
mmol/mol
4.00
149
1325
78
644
1.37
1.26
2.4
2.0
1.63
1.30
mmol/l
2.48
69
525
22
141
1.64
1.24
1.9
2.0
1.67
1.52
%
0.24
15
123
8
37
2.21
1.23
1.4
1.4
—
—
—
0
0
8
37
2.21
1.23
2.3
1.3
—
—
—
0
0
6
26
2.35
1.19
1.0
1.2
—
—
—
0
0
45
342
1.42
1.18
3.7
1.8
1.56
1.47
mg/l
0.09
34
269
5
20
2.54
1.16
3.0
1.6
—
—
—
0
0
5
20
2.54
1.16
1.6
1.2
—
—
—
0
0
7
33
2.16
1.07
3.9
2.2
246.86
266.38
e6/l
—
7
26
8
44
1.85
0.87
1.9
1.3
—
—
—
0
0
154
1452
1.38
0.83
7.2
5.3
6.54
6.01
mmol/l
3.86
144
1316
0
25
0.00
0.79
0.0
1.3
—
1.05
—
0
17
159
1510
1.40
0.79
8.1
5.8
2.37
2.67
mmol/l
3.88
152
1379
6
34
1.79
0.77
1.7
1.4
—
—
—
0
0
0
28
0.00
0.76
0.0
1.9
—
—
—
0
0
152
1438
1.34
0.73
36.2
16.2
63.11
77.38
ml/min/173m2
8.94
147
1347
5
25
2.03
0.73
1.4
1.8
—
—
—
0
0
25
187
1.39
0.73
4.1
5.0
5.10
61.05
ug/l
0.76
20
160
156
1483
1.35
0.71
7.1
5.1
4.24
4.55
mmol/l
2.98
149
1360
5
27
1.87
0.69
2.0
1.7
—
—
—
0
0
155
1478
1.32
0.64
7.0
5.0
1.26
1.44
mmol/l
6.24
148
1343
149
1417
1.28
0.60
6.2
4.3
1.77
1.25
mmol/l
9.00
140
1279
24
186
1.33
0.58
1.6
1.5
—
—
—
0
0
7
47
1.51
0.48
2.1
2.0
—
—
—
0
0
11
77
1.46
0.46
3.5
10.4
1.36
1.62
%
0.70
11
69
7
50
1.42
0.45
2.6
2.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
5
79
0.62
0.36
1.4
2.2
—
—
—
0
0
6
42
1.44
0.36
1.7
1.4
—
3.30
—
0
7
17
140
1.24
0.28
1.7
1.4
—
—
—
0
0
5
73
0.68
0.26
1.4
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
4.40
—
0
5
56
599
0.91
0.21
4.1
4.9
23.00
21.26
%
0.41
34
317
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
10
81
1.25
0.19
2.2
3.9
13.30
2217.85
u/ml
—
10
66
124
1206
1.09
0.17
56.9
22.3
329.97
332.35
g/l
1.74
124
1201
77
735
1.08
0.17
4.5
5.7
2.44
2.78
ug/l
0.19
70
655
10
88
1.14
0.08
1.1
1.3
—
37.46
—
0
10
21
216
0.97
0.00
6.0
4.8
28.44
32.76
%
1.14
16
136
14
141
0.99
0.00
1.4
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
6
67
0.89
-0.00
1.3
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
822.71
—
0
9
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
1.13
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
8.26
—
0
8
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYPERURI and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERURI | 2.552 [1.94, 3.35] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.157 |
During the follow-up period (1.1.1998 — 31.12.2019), 188 out of 407 females with E4_HYPERURI died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERURI | 2.743 [1.91, 3.95] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 494 males with E4_HYPERURI died.
Mortality risk
Mortality risk for people of age
years, who have E4_HYPERURI.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.153% | 0.478% |
| 5 | 1.103% | 2.974% |
| 10 | 3.035% | 7.543% |
| 15 | 5.976% | 13.46% |
| 20 | 10.95% | 22.07% |
Relationships between endpoints
↥Index endpoint: E4_HYPERURI – Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data